Decitabine Prior to Low-Dose Cytarabine-Based Chemotherapy Combined with HLA-Mismatched Stem Cell Micro-Transplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukaemia

Research Highlights • A new transplant style for elderly patients with newly diagnosed AML was proposed. • The transplantation consists of substantial decitabine plus G-CSF priming, low dose aclarubicin and cytarabine (DCAG) chemotherapy and human leukocyte antigen (HLA) mismatched stem cell micro-t...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2017
Main Authors: Zhu, Yu, MD, Zhao, Huihui, Ph.D candidate, Zhang, Xiaoyan, MD, PhD, Wu, Yujie, MD, PhD, Xie, Yue, Ph.D candidate, Li, Yanru, Ph.D candidate, Lian, Yun, Ph.D candidate, Huang, Jiayu, Ph.D candidate, Li, Jianyong, MD, PhD, Chen, Yaoyu, PhD, Qian, Sixuan, MD, PhD
Format: Article
Language:English
Subjects:
Hematology, Oncology and Palliative Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Research Highlights • A new transplant style for elderly patients with newly diagnosed AML was proposed. • The transplantation consists of substantial decitabine plus G-CSF priming, low dose aclarubicin and cytarabine (DCAG) chemotherapy and human leukocyte antigen (HLA) mismatched stem cell micro-transplantation (SC-MST). • The transplantation was well tolerated for elderly patients even for those with poor HCT-CI, graft-versus-host disease (GVHD) prophylaxis was not needed.
ISSN:1083-8791
DOI:10.1016/j.bbmt.2017.01.085